Compare CFG & RVMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CFG | RVMD |
|---|---|---|
| Founded | 1828 | 2014 |
| Country | United States | United States |
| Employees | 17398 | 883 |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.1B | 19.2B |
| IPO Year | N/A | N/A |
| Metric | CFG | RVMD |
|---|---|---|
| Price | $64.46 | $140.79 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 18 | 19 |
| Target Price | $70.17 | ★ $140.84 |
| AVG Volume (30 Days) | ★ 4.4M | 3.8M |
| Earning Date | 04-16-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.83% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $20.17 | N/A |
| Revenue Next Year | $8.30 | $533.02 |
| P/E Ratio | $16.85 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $36.72 | $34.00 |
| 52 Week High | $68.79 | $155.70 |
| Indicator | CFG | RVMD |
|---|---|---|
| Relative Strength Index (RSI) | 56.45 | 62.82 |
| Support Level | $58.09 | $93.39 |
| Resistance Level | $66.37 | $155.70 |
| Average True Range (ATR) | 1.42 | 7.53 |
| MACD | -0.10 | -0.07 |
| Stochastic Oscillator | 30.62 | 75.43 |
Citizens Financial Group Inc is a bank holding company headquartered in Providence, Rhode Island. Through its subsidiaries, it offers various retail and commercial banking products and services to individuals, small businesses, middle-market companies, large corporations, and institutions. The group's reportable business segments are: Consumer Banking and Commercial Banking. The majority of its revenue is generated from the Consumer Banking segment, which serves consumer customers and small businesses, offering traditional banking products and services, including deposits, mortgage and home equity lending, credit cards, small business loans, education loans, point-of-sale finance loans, and wealth management solutions, among others, through a network of branches and ATMs.
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.